Vedolizumab
Vedolizumab Basic information
- Product Name:
- Vedolizumab
- Synonyms:
-
- Vedolizumab
- Vedolizumab USP/EP/BP
- Research Grade Vedolizumab(DHC98802)
- Vedolizumab (anti-α4β7-integrin)
- Research Grade Vedolizumab
- Vedolizumab 62.6mg/ml
- CAS:
- 943609-66-3
- MW:
- 0
- Mol File:
- Mol File
Vedolizumab Chemical Properties
- storage temp.
- Store at -80°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to off-white
Vedolizumab Usage And Synthesis
Uses
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Clinical Use
Monoclonal antibody:
Treatment of ulcerative colitis and Crohn’s disease
in vivo
Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups[1].
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Metabolism
The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible.
References
[1] Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. DOI:10.1124/jpet.109.153973
[2] Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. DOI:10.4103/0976-9668.175016
VedolizumabSupplier
- Tel
- 27-027-83314682 13554138826
- whsrtech@vip.163.com
- Tel
- 027-59207852 13308628970
- buy@fortunachem.com
- Tel
- 025-57798810
- sales@sunlidabio.com
- Tel
- 028-81700200 18116577057
- 3003855609@qq.com
- Tel
- 15221275939
- shenlinxing@macklin.cn
Vedolizumab(943609-66-3)Related Product Information
- Follicle stimulating hormone
- Secukinumab
- Daratumumab
- OMALIZUMAB
- Dulaglutide
- Trastuzumab emtansine
- Ranibizumab
- palivizumab
- Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
- Eculizumab
- Matuzumab
- ticilimumab tremelimumab
- CNTO 148
- Aflibercept
- abciximab
- Avelumab
- nimotuzumab
- belimumab